11 February 2020 | News
MilliporeSigma will fund the research and development and be responsible for global commercialization
image credit- shuttershock.com
US based ReForm Biologics LLC, a pharmaceutical technology company developing innovative platforms to improve biologic formulations and MilliporeSigma have announced a global license agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations. The Life Science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
Under the agreement, MilliporeSigma and ReForm Biologics will conduct research, development and qualification of ReForm Biologics’ excipients for pharmaceutical use.
MilliporeSigma will fund the research and development and be responsible for global commercialization, GMP manufacturing, and sale of ReForm Biologics’ excipients to MilliporeSigma’s customers for use in biologic formulations.
ReForm Biologics will receive revenues from MilliporeSigma for sublicensing ReForm Biologics’ technology to MilliporeSigma’s customers in biologic formulations.